This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

NCT03448406 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure

Interventions

DRUG: Empagliflozin
DRUG: Placebo

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]